Loading stock data…
Progyny, Inc. (PGNY)
$31.19+0.49 (+1.60%)
Market ClosedLast close Jul 24
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Progyny, Inc. in the Healthcare sector is trading at $31.19 with a market capitalization of $2.0B. Wall Street consensus targets $32.45 (11 analysts), implying a +4.1% move over the next 12 months. The stock is currently near its 52-week high of $33.06, remaining 35.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $328.50M↑ | $318.40M↑ | $313.35M↓ | $332.87M↑ | $324.04M |
| Gross Profit | $83.07M↑ | $76.88M↑ | $72.83M↓ | $78.97M↑ | $75.80M |
| Operating Income | $35.38M↑ | $15.22M↓ | $21.53M↓ | $24.36M↑ | $24.17M |
| Net Income | $24.23M↑ | $12.48M↓ | $13.86M↓ | $17.11M↑ | $15.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cyc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
32.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.91
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.41%
Volume
Today's trading volume
623,233
Recent News
Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors
Disposition reduced her direct holdings by 5% through a combination of Rule 10b5-1 plan sales and tax-withholding shares, leaving her with a $2.26 million stake.
1 Cash-Producing Stock with Competitive Advantages and 2 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Progyny (PGNY) Stock May Be 50% Undervalued On Fresh Analyst Upgrades
Progyny stock has climbed strongly in the near term and reached a fresh 52 week high, yet there is a clear split in what the valuation checks say, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to sizable upside while earnings based multiples suggest the shares already trade at a premium. Over 5 years, Progyny has delivered a decline of 43.1%, which means long term holders have not yet shared in the recent momentum. Upgraded analyst views and a stronger earnings outlook...
Does Rising Analyst Optimism On June Trends Reframe Progyny’s (PGNY) Employer-Demand Story?
Earlier this week, several Wall Street firms issued upbeat research on Progyny, highlighting stronger June activity and signaling increased confidence in its upcoming earnings and guidance. This wave of positive analyst commentary underscores how closely investors are watching Progyny’s operating trends as a gauge of employer demand for fertility and family-building benefits. Next, we’ll examine how rising analyst optimism about June transaction trends could influence Progyny’s existing...
Stocks making big moves yesterday: RXO, Progyny, Cigna, GoodRx, and Domino's
Check out the companies making headlines yesterday: